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Abstract
Introduction: Most pregnant smokers report abruptly reducing their cigarettes per day
(CPD) by ~50% shortly after learning of pregnancy and of making further smaller
reductions over the remainder of their pregnancy. Laboratory and naturalistic studies with
non-pregnant smokers have found that these types of reductions often lead to changes in
smoking topography (i.e., changes in smoking intensity to maintain a desired bloodnicotine level). 19, 20 If pregnant women engage in compensatory smoking, they may
expose themselves and their offspring to the same level of toxicants despite reporting
reductions in CPD.
Methods: Pregnant and non-pregnant female smokers (n = 17 and 91, respectively)
participated. At the experimental session, after biochemical confirmation of acute
abstinence, all participants smoked one of their usual brand cigarettes ad lib through a
Borgwaldt CReSS Desktop Smoking Topography device. Carbon monoxide (CO) and
measures of nicotine withdrawal, craving, and reinforcement derived from smoking were
also collected.
Results: The two groups did not differ on any demographic or smoking characteristics at
screening, except nicotine metabolism rate, which as expected, was faster in pregnant
smokers. Analyses suggest that none of the smoking topography parameters differed
between pregnant and non-pregnant smokers, although pregnant smokers had a
significantly smaller CO boost. Both groups reported similar levels of relief of
withdrawal and craving after smoking, but other self-report data suggest that pregnant
smoker find smoking less reinforcing than non-pregnant smokers.
Conclusions: Pregnant smokers do not smoke cigarettes differently as compared to nonpregnant female smokers, but appear to find smoking less reinforcing.
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Comprehensive Literature Review

Smoking during pregnancy is the leading preventable cause of poor pregnancy
outcomes in the U.S. (U.S. Department of Health and Human Services [USDHHS],
2014). Women who smoke during pregnancy put themselves and their children at
increased risk for a wide range of poor outcomes (Dietz et al., 2010; Hackshaw, Rodeck,
& Boniface, 2011). Smoking while pregnant increases the risk of placental abruption,
placenta previa, and miscarriage (Aliyu et al., 2011; Pineles, Park & Samet,
2014). Adverse fetal and neonatal effects include intrauterine growth restriction, low
birth weight, preterm birth and birth defects (Cohen, Jeffery, Lagercrantz, & KatzSalamon, 2010; Dietz et al., 2010; Hackshaw et al., 2011) which contribute to longer, and
therefore more costly, postnatal hospital stays (Adams, Melvin, Raskind-Hood, Joski, &
Galactionova, 2011). The adverse consequences continue into childhood and beyond in
the form of increased risk for sudden infant death syndrome (SIDS), cognitive
impairments, obesity, metabolic syndrome, Type 2 diabetes, and cardiovascular disease
(Cohen et al., 2010; Bruin, Gerstein, & Holloway, 2010; Heinonen, et al., 2011; Moylan
et al., 2015).
Changes in Smoking during Pregnancy
Most pregnant women know that smoking during pregnancy increases adverse
outcomes for both the fetus/neonate and the mother (Arnold et al., 2001) and also report
being the target of strong social stigma (Abrahamsson, Springett, Karlsson, & Ottosson,
2005; Wigginton & Lee, 2013). Nonetheless, most women cannot quit smoking on their
own after learning of pregnancy (Heil et al., 2014; Solomon & Quinn, 2004). Instead,
1

most report spontaneously reducing their cigarette use in an effort to reduce fetal toxicant
exposure (Graham, Flemming, Fox, Heirs, & Sowden, 2014). Across a wide variety of
studies, the majority of pregnant smokers reliably report decreasing their cigarettes per
day (CPD) by approximately 50% between learning of pregnancy and entering prenatal
care (Coleman et al., 2012; Dornelas et al., 2006; Heil et al., 2008; Higgins et al., 2004;
Higgins et al., 2014; Pollak et al., 2007; Rigotti et al., 2006; Ussher et al., 2015) and
recent work by our group examined the time course of this change for the first time (Heil
et al., 2014). In our research clinic, women enrolling in clinical trials testing whether
financial incentives increase abstinence in pregnant smokers complete a timeline followback interview where they retrospectively self-reported their CPD each day between
when they learned they were pregnant and when they entered prenatal care an average of
five weeks later. This analysis specifically characterized the timing of CPD reductions in
the days after learning
of pregnancy in 107 of
these women. Results
indicated that 22%
reported quitting
smoking between
learning of pregnancy
and entering prenatal
care, 62% significantly
reduced the number of

Figure 1. Mean ± standard error of the mean for cigarettes/day before and after learning
of pregnancy among women who self-report reducing cigarettes/day upon learning of
pregnancy. Adapted from “Examining the timing of changes in cigarette smoking upon
learning of pregnancy,” by S. H> Heil, E.S. Herrmann, G. J. Badger, L. J. Solomon, I.
M. Bernstein, S. T. Higgins, Preventive Medicine, 68, 58-61.
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cigarettes they smoked each day, and 16% reported making no changes in their smoking
at all during this time period. Focusing on those who reduced, as expected, most reported
a characteristic 50% reduction in CPD. Interestingly, most of this reduction occurred in
the first two days after learning of pregnancy (Figure 1), a remarkable reduction over a
short period given the persistent and tenacious nature of cigarette smoking. A potential
limitation of these data is our use of self-reported CPD. As noted previously, stigma
could be expected to contribute to some extent of under-reporting of smoking rates,
although this clearly did not prevent the majority of participants from reporting continued
smoking and a sizeable percentage from reporting that they had not changed their
smoking at all since learning of pregnancy. Nevertheless, without biochemical data, it is
difficult to know whether self-reported reductions in CPD truly decrease toxicant
exposure.
Correspondence between Self-Report and Biochemical Measures of Cigarette Use.
To examine this further, we conducted another analysis where the correspondence
between self-report and biochemical measures of smoking could be assessed (Heil,
Solomon, Skelly, Bernstein, & Higgins, 2015). Data were collected from a different set of
pregnant women participating in the same series of randomized clinical trials testing
financial incentives for smoking cessation described above. CPD and biochemical
measures of smoking were examined among a subset of 156 women who reported
smoking and had complete data at each of three research assessments completed during
the pregnancy, the first at Intake at ~10 weeks gestation, the second four weeks later
(Early Pregnancy), and the third at approximately ~28 weeks gestation (Late Pregnancy).
3

The biochemical measures of
smoking were breath carbon
monoxide (CO) and urine
cotinine. CO is one of the
primary toxic components of
cigarette smoke. The elimination
half-life of CO is only a few
hours (Jarvis, Tunstall-Pedoe,
Feyerabend, Vesey, & Saloojee,
1987), thus levels are indicative
of very recent smoking.
Cotinine is the primary

Figure 2. Mean ± SEM urine cotinine in nanograms per milliliter, breath CO in parts
per million and cigarettes per day at ~ 10 weeks estimated gestational age (Intake), ~
14 weeks estimated gestational age (Early Pregnancy) and ~26 weeks estimated
gestational age (Late Pregnancy). Data points with letters in common are not
statistically different from one another. Repeated measures ANOVAs indicated a
significant effect of time on urine cotinine and CPD but not CO. Data points with
letters in common were not statistically different from one another in post hoc
analyses. Adapted from “Correspondence between Self-Report and Biochemical
Measures of Cigarette Use in Pregnant Women” by S. H. Heil, L. J. Solomon, J. M.
Skelly, I. M. Bernstein, & S. T. Higgins, presented at the College on Problems of
Drug Dependence Annual meeting, June 2015.

metabolite of nicotine. The elimination half-life is approximately five times longer than
that of CO (Dempsey, Jacob & Benowitz, 2002), making it a better measure of smoking
over the last few days. On average, women in this analysis reported further significant
reductions in CPD, from 11 CPD at Intake to 7-8 CPD at the Early and Late Pregnancy
assessments (Figure 2). Despite this significant 31% decrease in CPD between the Intake
and Early Pregnancy assessments, however, urine cotinine only decreased by 10% and
breath CO did not change appreciably. At the Late Pregnancy assessment, urine cotinine
was not statistically different from Early Pregnancy assessment.
Prior studies of the correspondence between self-report and biochemical measures
of smoking in pregnant women have often reported similar discrepancies and have
4

frequently hypothesized that (1) inaccurate self-report, (2) changes in metabolism, and/or
(3) changes in smoking topography account for these inconsistencies (Boyd, Windsor,
Perkins & Lowe, 1998; Dukic, Niessner, Benowitz, Hans, & Wakschlag, 2007; Ellard,
Johnstone, Prescott, Ji-Xian, & Jian-Hua, 1996; Klebanoff, Levine, Clemens,
DerSimonian, & Wilkins, 1998; Lindqvist, Lendahls, Tollbom, Aberg, & Hakansson,
2002; Pickett, Rathouz, Kasza, Wakschlag, & Wright, 2005). In the sections that follow,
current knowledge about each of these potential explanations is briefly reviewed.
Inaccurate Self-Report among Pregnant Smokers. As with the use of any
drug, it is not recommended to rely on self-report of smoking as participants may be
unable or unwilling to accurately report use (Connor Gorber, Schofield-Hurwitz, Hardt,
Levasseur, & Tremblay, 2009; Magura & Kang, 1996; National Institute of Drug Abuse,
2012). As a result, self-report is often verified by biochemical markers of smoking like
breath CO and urine cotinine. Many studies have examined the relationship between
self-report and biochemical markers of smoking among pregnant women and used these
data to estimate the rate of inaccurate reporting in terms of smoking status (i.e.,
differentiating smokers from nonsmokers) as well as smoking rate (e.g., differentiating
lighter, moderate, and heavier smokers from each other). One review of 15 studies found
that the rate of inaccurate self-report of smoking status ranged between 0-35%, with a
median of 21% (Russell, Crawford, & Woodby, 2004). There are fewer studies
examining smoking rate, but similar to smoking status, correlations between CPD and
biochemical markers tend to vary widely, with a range of .32 - .74 and a median of .44
(Boyd et al., 1998; Ellard et al., 1996; Klebanoff et al. 1998; Pickett et al., 2005). Given
5

strong social stigma against smoking during pregnancy, it is not surprising that pregnant
women might underreport smoking status and rate. But because estimations of
underreporting are based on studies of the relationship between self-report and levels of
biochemical markers, and levels of biochemical markers could be altered by metabolism
and topography differences during pregnancy, it has remained unclear how much of the
discrepancy between self-report and biochemical markers is due to true inaccurate selfreport and how much could be due to confounding changes in metabolism and/or
smoking topography. In fact, most of the studies in this literature have used biochemical
cut points that were based on cut points established for non-pregnant smokers as there
were few data on metabolism and topography during pregnancy to guide adjustments. In
the next two sections, the extant data on metabolism and topography during pregnancy
are reviewed.
Changes in Metabolism among Pregnant Smokers. Dempsey and colleagues
conducted the seminal study of nicotine and cotinine metabolism during the perinatal
period. In this within-subject study, pregnant women were admitted inpatient and infused
with labeled nicotine and cotinine to determine the pharmacokinetics of each drug. The
procedure was then repeated during the postpartum period. Given the common report of
substantial smoking reductions among pregnant women, the authors hypothesized that
nicotine and cotinine metabolism would be slower during pregnancy. Surprisingly, the
data indicated higher rates of metabolism during pregnancy as compared to postpartum
(Dempsey et al., 2002). For example, nicotine clearance was 60% faster during
pregnancy vs. postpartum. While this study documented this change for the first time,
6

the design of the study left the timing of the change unclear.
A recent longitudinal cohort study by Bowker and colleagues (2015) begins to
help clarify the timing (Bowker, Lewis, Coleman & Cooper, 2015). Rather than infusing
nicotine and directly measuring subsequent metabolism, these investigators used a
simple, but validated, method to estimate nicotine metabolism in biological matrices
known as the nicotine metabolite ratio (NMR; Dempsey et al., 2004; Levi, Dempsey,
Benowitz, & Sheiner, 2007). NMR is calculated by dividing the level of trans-3’hydroxycotinine, the primary metabolite of cotinine, by the level of cotinine. In the
Bowker et al. (2015) study, pregnant women (N=101) were asked to provide saliva
samples at three time points throughout their pregnancy and twice postpartum. Each
sample was assayed for trans-3’-hydroxycotinine and cotinine and an NMR was
calculated. Compared to their NMR at 12 weeks postpartum, NMR approached statistical
significance at 8-14 weeks and was significantly higher at 18-22 and 32-36 weeks
estimated gestational age, but was lower and not significantly different at 4 weeks
postpartum. These results confirm Dempsey et al.’s findings of higher rates of
metabolism during pregnancy and further suggest that nicotine metabolism accelerates
very early in the pregnancy, remains elevated throughout the pregnancy, and returns to
lower levels early in the postpartum period.
More recently, our group examined the time course of NMR changes during
pregnancy and postpartum. Forty-six women enrolled in a trial to test the effectiveness of
financial incentives to increase abstinence among pregnant smokers and who continued
to smoke during pregnancy and into postpartum provided urine samples at two
7

assessments during pregnancy at ~10 weeks and ~28 weeks estimated gestational age and
one assessment at 6 months postpartum. Consistent with the two earlier reports, NMR
was significantly higher at both pregnancy assessments compared to the postpartum
assessment. Additionally, NMR was significantly higher at the later pregnancy
assessment compared to the earlier pregnancy assessment, adding credence to the
borderline trend observed by Bowker and colleagues. Since metabolism appears to
increase throughout the antepartum period, it is unlikely that metabolism differences
explain the discrepancies between self-report and biochemical measures of smoking
described above.
Changes in Smoking Topography among Pregnant Smokers. To our
knowledge, there are no data examining smoking topography in pregnant smokers.
However, data from non-pregnant smokers suggests that reductions in CPD like those
reported by pregnant smokers might lead to changes in smoking topography. In a
rigorous laboratory study on this topic, participants who normally smoked 37 CPD during
unrestricted use were given only 15, 10 and 5 cigarettes a day while residing on an
inpatient clinical research ward (Benowitz, Jacob, Kozlowski & Yu, 1986). Researchers
collected urine and blood samples at regular intervals to measure changes in the levels of
tar (a toxic byproduct of combusted tobacco), nicotine, and carboxyhemoglobin
(indicative of decreased oxygen delivery throughout the body). Of particular interest here
are the changes in these measures of cigarette exposure when participants went from
smoking 37 CPD to 15 CPD, a 60% reduction, as this reduction most closely
approximates the 50% reduction typically reported by pregnant smokers upon learning of
8

pregnancy (Heil et al.,
2014 and Figure 1 in
this document). When
participants in the
Benowitz et al. study
decreased their CPD
by 60%, tar, nicotine,
and
carboxyhemoglobin
levels only decreased
by 15%, 32%, and

Figure 3. Percent change in cigarettes, tar, nicotine and carboxyhemoglobin
per 24 hours during unrestricted and restricted cigarette use. Significant
differences are indicated by an asterisk. Adapted from “Influence of smoking
fewer cigarettes on exposure to tar, nicotine and carbon monoxide.” By N. L.
Benowitz, P. Jacob, L. T. Kozlowski, & L. Yu, 1986, The New England
Journal of Medicine, 315, 1310-1316.

26%, respectively (Figure 3). While statistically significant, these decreases were not
proportional to the reduction in CPD. It was also notable that none of the participants
reported any difficulty smoking just 15 CPD, with some participants quoted as saying it
was “no hardship” and that it was “very easy”. Similar, but more extreme results were
observed when smokers were limited to 10 and 5 CPD (73% and 86% reductions,
respectively). The authors concluded that participants changed their smoking topography
when the number of CPD was limited, likely by puffing on each cigarette more
frequently and/or more intensely, to maintain their desired nicotine blood levels.
A similar conclusion was reached in a more naturalistic longitudinal analysis of
cross-sectional data collected in the National Health and Nutrition Examination Survey.
The authors compared daily CPD and levels of serum cotinine in nationally
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representative samples of cigarettes smokers assessed between 1988-1994 to those
assessed between 1999-2012 (Jarvis, Giovino, O’Connor, Kozlowski & Bernert, 2014).
The results indicated that mean CPD decreased significantly over time from 17.3 to 13.9
CPD, a 20% reduction, very similar to the changes reported by pregnant smokers in early
pregnancy (Heil et al., 2015 and Figure 2 in this document). However, serum cotinine
levels were not significantly different, decreasing from 223.7 to just 219.2 ng/ml, a 2%
reduction. The authors conclude that these results are suggestive of increased inhalation
to offset reduced cigarette consumption. Together, the results of these two studies
suggest that smokers maintain nicotine exposure after reducing their CPD by engaging in
compensatory smoking, which in turn continues to expose them to similar levels of
toxicants.
Current Study
Whether changes in smoking topography help account for the apparent
discrepancies between self-reported CPD and biochemical markers of smoking among
pregnant smokers has not been examined to date to our knowledge. If it is determined
that pregnant women do smoke cigarettes more intensely than non-pregnant women,
these changes may offset presumed benefits of reductions in self-reported CPD.
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ABSTRACT
Introduction: Most pregnant smokers report abruptly reducing their cigarettes per day
(CPD) by ~50% shortly after learning of pregnancy and of making further smaller
reductions over the remainder of their pregnancy. Laboratory and naturalistic studies with
non-pregnant smokers have found that these types of reductions often lead to changes in
smoking topography (i.e., changes in smoking intensity to maintain a desired bloodnicotine level). 19, 20 If pregnant women engage in compensatory smoking, they may
expose themselves and their offspring to the same level of toxicants despite reporting
reductions in CPD.
Methods: Pregnant and non-pregnant female smokers (n = 17 and 91, respectively)
participated. At the experimental session, after biochemical confirmation of acute
abstinence, all participants smoked one of their usual brand cigarettes ad lib through a
Borgwaldt CReSS Desktop Smoking Topography device. Carbon monoxide (CO) and
measures of nicotine withdrawal, craving, and reinforcement derived from smoking were
also collected.
Results: The two groups did not differ on any demographic or smoking characteristics at
screening, except nicotine metabolism rate, which as expected, was faster in pregnant
smokers. Analyses suggest that none of the smoking topography parameters differed
between pregnant and non-pregnant smokers, although pregnant smokers had a
significantly smaller CO boost. Both groups reported similar levels of relief of
withdrawal and craving after smoking, but other self-report data suggest that pregnant
smoker find smoking less reinforcing than non-pregnant smokers.
12

Conclusions: Pregnant smokers do not smoke cigarettes differently as compared to nonpregnant female smokers, but appear to find smoking less reinforcing.
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INTRODUCTION
Maternal cigarette smoking is the leading preventable cause of poor pregnancy
outcomes.1 Despite this, approximately 15% of pregnant women are regular cigarette
smokers. Fifty percent reductions in cigarettes per day (CPD) in early pregnancy have
been reliably reported across many studies.2-6 In one study by our group, pregnant women
self-reported that the bulk of this change in smoking behavior takes place within the first
few days after learning of their pregnancy.7 Surprisingly, this reduction in CPD occurs
despite an increase in the metabolism of nicotine during pregnancy;8, 9 in non-pregnant
populations, higher rates of nicotine metabolism are associated with smoking more
CPD.10
While pregnant smokers report making reductions in CPD to reduce harm to their
offspring,11 previous research indicates that self-reported reductions do not necessarily
correspond with toxicant reduction. Data from our research group indicate that selfreported reductions in CPD among pregnant smokers enrolled in a clinical trial to
increase abstinence with financial incentives are not always paralleled by the same level
of reduction in biochemical markers of smoking.12 Specifically, despite having reported a
one third reduction in CPD between 10 weeks and 14 weeks gestation, urine cotinine
levels among those pregnant smokers reduced by only 10% and carbon monoxide (CO)
levels remained unchanged. Research by others tells a similar story: correlations between
CPD and biochemical markers tend to vary widely among pregnant smokers, with a range
across reports of .32 - .74 and a median of .44.13-16
14

One commonly cited potential explanation for variations in the relationship
between nicotine exposure and CPD is that pregnant smokers change their smoking
topography (e.g., increase the number of puffs per cigarette, the duration of each puff, the
volume of each puff, etc.) in an effort to maintain the same blood nicotine level despite
smoking fewer CPD (i.e., compensatory smoking).13-18 To our knowledge, no studies
have examined smoking topography among pregnant smokers, but evidence from
laboratory studies and naturalistic studies with non-pregnant smokers report similar
discrepancies between the level of reduction in CPD and the level of reductions in
smoking biomarkers that have been attributed to changes in smoking topography.19, 20 If
pregnant women engage in compensatory smoking, they may expose themselves and
their offspring to the same level of toxicants despite reporting reductions in CPD. The
present study compared the smoking topography of usual brand cigarettes in nonpregnant women of low socioeconomic status (SES) to pregnant smokers who have
reported reductions in their CPD since learning of their pregnancy.
METHOD
Participants and Inclusion/Exclusion Criteria
Pregnant and non-pregnant smokers were recruited via ads on Facebook,
Craigslist, and in local newspapers; flyers on community bulletin boards; and from a
local OB/GYN clinic. All potential participants completed a brief phone screen and those
who appeared eligible were invited to attend an in-person screening session to determine
final eligibility. After providing informed consent, participants submitted breath samples
15

(Micro+ Smokerlyzer; coVita/Bedfont, Haddonfield, NJ) and urine samples (NicAlert
cotinine test strip; Nymox, Hasbrouck Heights, NJ) to verify smoking status. Urine was
also tested to determine pregnancy status and to quantify cotinine levels via enzyme
immunoassay (MGC240; Microgenics, Fremont, CA). Additionally, participants
provided saliva samples which were analyzed for cotinine and trans-3’-hydroxycotinine
(3-HC), the major metabolite of cotinine. 3-HC was divided by cotinine to calculate a
nicotine metabolite ratio (NMR), which is strongly correlated with nicotine clearance.21
Next, potential participants completed demographic (e.g., age, race/ethnicity,
education, marital status, etc.) and medical history questionnaires developed in our
laboratory, and then filled out a series of standardized questionnaires about their tobacco
use, including the Fagerstrӧm Test for Nicotine Dependence 22-24 (see Appendix A).
Eligible non-pregnant participants had to self-report smoking at least 5 CPD for
the past year and have an intake breath CO sample > 8 ppm. There was no minimum
CPD or breath CO level for the pregnant participants. Rather, smoking status was
confirmed among pregnant participants with a urine cotinine value > 100 ng/ml (> 2 on
NicAlert strip). Low SES was also an inclusion criterion because socioeconomically
disadvantaged women are at increased risk for (1) smoking, (2) nicotine dependence, (3)
smoking more CPD, (4) smoking higher nicotine yield cigarettes and (5) continuing to
smoke after becoming pregnant. 25, 26 Education level served as a proxy for SES and all
participants had to have less than an Associate’s degree. Individuals were excluded if
they reported exclusively rolling their own cigarettes, if they reported using other tobacco
16

or nicotine products more than 9 days in the last 30 days, if they reported intentions to
quit in the next 7 days if pregnant and 30 days if non-pregnant, or if they reported any
smoking cessation product use in the last 30 days. All participants were without current
serious mental disorder. Participants also could not show evidence of recent illicit drug
use, but opioid-dependent women who were stable in opioid agonist maintenance
treatment were eligible. “Stable” was defined as having (1) >70% of urine drug screens in
the past month negative for all drugs of abuse and (2) been on the same methadone or
buprenorphine dose for the past 7 days if pregnant and 30 days if not pregnant. Pregnant
women experience an acceleration in the metabolism of opioid agonist medication during
pregnancy, so dose increases to prevent opioid withdrawal are not uncommon.27, 28.
Stability in treatment was confirmed with treatment providers. All potential participants
were compensated $50 for completing the screening session.
Procedures
If deemed eligible, participants were invited back for an experimental session.
Participants were instructed to abstain prior to the session and had to meet at least a 50%
reduction in their screening breath CO level in order to begin the experimental session;
this criterion is widely used as a marker of acute abstinence in smoking research.29, 30
After abstinence was confirmed, all participants took two puffs from their usual brand
cigarette to equate time since last cigarette. Thirty minutes after taking two puffs,
participants smoked one usual brand cigarette through a CReSS Desktop smoking
topography device (Borgwaldt, Richmond, VA) with no instruction (i.e., ad libitum
17

puffing) (see Appendix B). The device measured and recorded a number of smoking
topography parameters, namely: (1) number of puffs per cigarette, (2) puff duration, (3)
inter-puff interval, (4) puff volume and (5) maximum puff velocity (see Appendix C).
The CReSS smoking topography device has been shown to have good reliability and
validity.31, 32 This part of the session took place in a room with a ventilation system
specifically designed to allow for cigarette smoking indoors.
Immediately after smoking the cigarette, participants completed the modified
Cigarette Evaluation Questionnaire (mCEQ). The mCEQ consists of 12 items which
query how smoking the cigarette made the participant feel (e.g., “Did the cigarette taste
good?”, “Did the cigarette help you concentrate?”) (see Appendix D). 33 Designated items
are averaged to generate five subscale scores, namely (1) Satisfaction, (2) Psychological
Reward, (3) Aversion, (4) Enjoyment of Respiratory Tract Sensations and (5) Craving
Reduction. The measure has demonstrated good reliability and validity. 34
CO was collected in 15-minute increments in the hour that followed smoking to
assess CO boost, another measure of smoke exposure and intensity of smoking.35, 36 To
measure CO boost, pre-cigarette CO was subtracted from each CO value measured after
smoking the cigarette. Withdrawal and craving were also measured in 15-minute
increments using the Minnesota Nicotine Withdrawal Scale (MNWS) and Questionnaire
of Smoking Urges-Brief Scale (QSU). The MNWS measured eight nicotine withdrawal
symptoms (e.g., craving, irritability, anxiety) (see Appendix E).37-39 Mean withdrawal is
derived as the average of seven of the eight symptoms (range, 0-4), with the item “Desire
18

or Craving to Smoke” analyzed separately.40 Previous studies have shown this measure
has good reliability and validity.37-39 The QSU is comprised of 37 statements indicating
current cravings to smoke (e.g., “A cigarette would taste good right now.”, “I could
control things better right now if I could smoke.”) (see Appendix F). 41, 42 The instrument
is scored such that two factors are derived, with Factor 1 often described as a measure of
the positive reinforcing effects of smoking and Factor 2 a measure of the negative
reinforcing effects of smoking. Previous studies have indicated that it is a reliable and
valid measure of smoking urges.42, 43
Participants were compensated for their time and for successfully abstaining prior
to the experimental session. Pregnant participants ended their participation after this
session. For non-pregnant women, this session was their first in a larger 14-visit study
designed to test the acute effects of cigarettes with varying nicotine levels. Data from
later sessions completed by non-pregnant women have been reported elsewhere.44
Statistical Method
Independent t-tests and Fisher’s exact tests were used to compare demographic
and smoking characteristics between the two groups.
All topography measures were log-transformed to meet normal distribution
requirements so that parametric tests could be used to compare the two groups. Smoking
topography measures were compared using independent t-tests. To explore whether
topography changes as a function of increasing gestational age, a Pearson product19

moment correlation coefficient was computed to assess whether estimated gestational age
(EGA) and any of the smoking topography parameters were related.
The five mCEQ subscales were compared between pregnant and non-pregnant
smokers using independent t-tests. CO boost, mean total MNWS score, MNWS item
‘desire to smoke’, QSU Factor 1 and QSU Factor 2 were compared between the two
groups and across time points using repeated measures analysis of variance, with time as
the within-subjects factor and pregnancy status as the between-subject factor. CO boost
was also characterized and compared using area under the curve. To do so, trapezoids
were constructed with the x- and y-axis coordinates for each data point and the combined
area of the three trapezoids summed.
Significance for all tests was set at p < .05.
RESULTS
Participant Characteristics
Seventeen pregnant and 91 non-pregnant female smokers completed the
experimental session. The two groups were remarkably similar on demographic and
smoking characteristics. On average, participants were 30 years old, Caucasian, had a
high school education or less, and were unmarried (Table 1). Women in both groups had
an average body mass index of 33, which falls in the overweight range. One-third of
participants were opioid-maintained. Pregnant smokers were 24 weeks EGA on average.
All but one of the smoking characteristics examined did not differ significantly between
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groups. At screening, both groups reported smoking approximately 14 CPD, with
pregnant women reporting cutting down from smoking 22 CPD prior to pregnancy (a
43% reduction). Women in both groups also tended to smoke high nicotine yield, nonmenthol cigarettes, had moderate levels of nicotine dependence, started smoking around
15 years of age and had average urine cotinine levels of 850 ng/ml. The only significant
difference between groups was on NMR, which was, as expected, significantly higher
among pregnant smokers as compared to non-pregnant smokers (p = .01). 8, 9
Smoking Topography
There were no statistically significant differences in smoking topography between
pregnant and non-pregnant women, with differences across parameters averaging less
than 5% (Figure 1). Within the pregnant smoker sample, there were no significant
correlations between EGA and topography measures.
CO boost was significantly higher in non-pregnant as compared to pregnant
smokers (p < .05) and decreased in a parallel fashion in both groups over time (p < .001;
Figure 2). Area under the curve analyses indicated CO boost was 24% higher among nonpregnant as compared to pregnant smokers (p < .05).
mCEQ
Of the five subscales, only the Satisfaction subscale was significantly different,
with lower scores among pregnant women as compared to non-pregnant women (p <
.001; Figure 3). Although not significant, pregnant women also trended towards higher
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scores on the Aversion subscale and lower scores on the Enjoyment of Respiratory Tract
Sensations subscale as compared to non-pregnant women (ps = .06 and .07, respectively).
MNWS
There were no significant differences between groups on mean MNWS scores or
on the MNWS item “Desire or Craving to Smoke”. Both groups did report significant
changes over time on these measures, with decreased scores 15 min after smoking the
cigarette followed by increasing scores across subsequent time points (p < .001; Figure 4,
top panel). This U-shaped function is consistent with acute relief of withdrawal after
smoking a cigarette.
QSU
There were significant differences between groups on both QSU Factor 1 and
QSU Factor 2 scores. While scores on both factors appeared equivalent in both groups
prior to smoking a usual brand cigarette through the CReSS device, after smoking,
pregnant women reported significantly lower positive and negative reinforcing effects of
smoking as compared to non-pregnant smokers (ps < .001; Figure 4, bottom panel).
Scores in both groups then increased in a parallel fashion across subsequent time points
on both factors (ps < .001; Figure 4, bottom panel).
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DISCUSSION
To our knowledge, this was the first study comparing the smoking topography of
pregnant and non-pregnant smokers. Despite reporting decreases in their CPD and
experiencing increases in nicotine metabolism rate, there were no differences in smoking
topography between pregnant and non-pregnant female smokers. Although no differences
were observed on any topography parameters, pregnant smokers had a smaller CO boost,
suggesting they may experience less toxicant exposure per cigarette. This smaller CO
boost may be explained by changes in the respiratory system during pregnancy that are a
response to increased demand for oxygen for the fetus and the mother. 45 These
adaptations are largely facilitated by hormonal and anatomical changes. For example,
progesterone has been shown to heighten central nervous system chemoreceptor
sensitivity to CO2. As another example, as the uterus expands, the diaphragm elevates
and the subcostal angle (the upside-down ‘V’ shaped section below the sternum) widens.
Together, these changes lead to a decreased residual volume (the air left in the lungs after
an exhale) and increased inspiratory capacity (the amount that can be inhaled after
normal expiration), thereby increasing overall tidal volume (the total amount of air in one
inhale and one exhale combined). Since there were no differences in smoking
topography between groups in the present study, it suggests that pregnant smokers take in
the same amount of cigarette smoke, including CO, from smoking one cigarette as nonpregnant smokers. However, because pregnant smokers have a larger tidal volume, more
CO can be exhaled with every breath, leading to a smaller CO boost. Observation of a
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smaller CO boost is also consistent with evidence from our group and others suggesting
that CO levels associated with abstinence are lower in pregnant smokers compared to
non-pregnant smokers.46, 47 In sum, it appears that pregnant smokers may experience less
exposure to toxicants like CO after smoking, although not by way of changes in smoking
topography.
Across self-report questionnaires, two overarching findings emerged. The first
was that both groups experienced similar levels of relief from withdrawal and craving
after smoking, with consistent results from the mean total MNWS and the mCEQ
Psychological Reward subscale (despite the title, four of the five items on this subscale
ask about withdrawal symptoms also queried on the MNWS) regarding withdrawal and
consistent results from the MNWS “Desire or Craving to Smoke” item and the mCEQ
Craving Reduction subscale regarding craving. The second overarching finding was that
multiple self-report measures suggested that pregnant smokers do not find smoking as
reinforcing (either positively or negatively) as non-pregnant smokers. QSU Factor 1 and
2 scale scores, measures of the positive and negative reinforcing effects of smoking, were
lower among pregnant smokers, as were mCEQ Satisfaction subscale scores. The
observation of trends towards lower scores on mCEQ Enjoyment of Respiratory Tract
Sensations subscale and higher scores on mCEQ Aversion subscale among pregnant
smokers added to this overall picture of smoking being less reinforcing for this group. It
is possible that decreases in the overall enjoyment of cigarette smoking facilitates the
substantial reductions most female smokers report during pregnancy and may also
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explain why they do not engage in compensatory smoking following such dramatic
reductions.
It was surprising that baseline cotinine levels did not differ between pregnant and
non-pregnant smokers. While both groups reported smoking about the same number of
CPD, NMR was 30% faster among pregnant smokers, suggesting that their cotinine
levels should have been lower if they were smoking approximately the same number of
CPD and given no differences in smoking topography. This discrepancy suggests that
there may still be some social pressure on pregnant smokers to underreport their level of
smoking even if they are not seeking treatment and have declared they do not have
intentions of quitting for at least another week.
The present data provide a unique opportunity to explore potential differences in
exposure between the socioeconomically disadvantaged women who participated in the
current study and general population smokers. One prior study that collected smoking
topography measures in general population male and female smokers (education level not
specified) under conditions similar to the present study (i.e., same smoking topography
device, following acute abstinence) reported that they had a total puff volume (average
puff volume X average number of puffs) of 553 ml.31 In comparison, the
socioeconomically disadvantaged pregnant and non-pregnant smokers in the current
study had average total puff volumes of 782 ml and 808 ml, respectively, approximately
30% higher. As previously described, socioeconomically disadvantaged women are
known to be at increased risk for (1) smoking, (2) nicotine dependence, (3) smoking more
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CPD, (4) smoking higher nicotine yield cigarettes and (5) continuing to smoke after
becoming pregnant, all of which contribute to worse health outcomes in this population.
31, 32

The present data suggest that how they smoke may also contribute to these poor

outcomes.
These findings should be considered in light of some limitations. First, the
pregnant sample in this study is relatively small. However, previous studies with similar
sample sizes have found differences in smoking topography.31, 48 Additionally, the control
group was closely matched on a number of demographic and smoking characteristics
which eliminated variability that may have made it more difficult to detect differences
between the groups. Furthermore, the differences in topography measures between nonpregnant and pregnant smokers were relatively small (< 5% on average), which does not
suggest that the study was underpowered. Another potential limitation involves
collecting smoking topography data through the CReSS device in a laboratory setting.
Research is inconsistent on whether smoking a cigarette in an artificial laboratory
environment alters smoking behavior.49, 50 Even if smoking through the CReSS device is
not perfectly representative of smoking in the natural environment, the fact that both
groups smoked through these devices allows relative comparisons of their smoking
topography to be made.
This study has notable strengths and makes a contribution to the scientific
literature. To our knowledge, it is the first study to capture a variety of variables during a
single cigarette smoking bout among pregnant smokers. Specifically, this study
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documented (1) smoking topography of usual brand cigarettes, (2) changes in CO in the
hour that followed smoking, and (3) subjective effects of this smoking bout. Most
noteworthy among these is smoking topography. For the past 20 years, researchers have
speculated about whether pregnant smokers engage in compensatory smoking. This was
the first study to directly address this question. In addition, a large sample of nonpregnant female smokers who did not differ from the pregnant smokers on important
demographic or smoking characteristics was included for comparison. More generally,
the present study speaks to the importance of using a variety of approaches to research
smoking during pregnancy. The overwhelming majority of the research conducted to
date has been randomized controlled trials testing interventions to promote cessation
during pregnancy. While this is understandable to some degree given the serious adverse
consequences of smoking during pregnancy, a recent Cochrane Review found 72 such
trials conducted over more than 30 years with more than 20,000 pregnant smokers and
reported that these interventions have only produced an average 6% increase in
abstinence compared to control conditions. 51 The present study underscores the
importance of conducting laboratory and other types of studies to help better understand
smoking during pregnancy, research that may lead to more efficacious treatments in the
future.
There are a number of future directions that could be explored. First, in regards to
studying smoking topography during pregnancy, future studies should replicate this study
in different contexts. For example, smoking topography can be measured using a
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portable version of the CReSS device used in the present study that can be sent home
with participants to record data across multiple smoking bouts in the participant’s normal
smoking environment. These studies would help validate the findings reported in this
paper. Additional studies are also needed to more firmly establish the relationship
between CPD and biochemical markers of smoking during pregnancy. A recent study by
Denlinger and colleagues (2016) assessed non-pregnant smokers in a controlled, but not
entirely artificial, environment (i.e., a hotel that permitted smoking) for 5 days.52 This
study allowed researchers to precisely quantify how many CPD participants smoked and
the levels of cotinine and other biomarkers that resulted. A similar study with pregnant
women could generate population estimates that could be used for research and clinical
purposes.
In summary, results of the present study suggest that the smoking topography of
pregnant smokers does not differ from that of non-pregnant female smokers and that
pregnant smokers find smoking less reinforcing. These changes in reinforcement may
help pregnant smokers make the substantial reductions in CPD typically reported during
pregnancy and may also protect them from engaging in compensatory smoking.
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Table 1. Demographics and smoking characteristics.
Pregnant
(n=17)

NonPregnant
(n=91)

p value

Demographics
Age
% White
% High school graduate or less
% Never married
Body mass index
% Opioid-dependent
Estimated weeks gestational age

30.4 ± 4.9
94
59
71
34.8 ± 22.2
41
24.1 ± 9.5

30.2 ± 7.0
96
52
57
31.1 ± 6.6
32
N/A

.89
.55
.56
.62
.18
.58

22.4 ± 8.5

N/A

12.9 ± 5.8
1.0 ± 0.4
25
4.1 ± 0.5
14.7 ± 3.5

15.3 ± 5.7
1.1 ± 0.2
24
4.6 ± 2.2
15.6 ± 3.0

.12
.59
.98
.35
.26

785.4 ± 546.2
0.62 ± 0.29

920.5 ± 488.7
0.46 ± 0.35

.27
.01

Smoking Characteristics
Pre-pregnancy cigarettes per day
Cigarettes per day at screening
Nicotine yield for usual brand cigarette
% Menthol
Fagerström Test for Nicotine Dependence
Age first started smoking
Biochemical Measures
Urine cotinine (ng/ml)
Nicotine metabolite ratio

Note: Values in the table are reported as means ± standard deviations unless otherwise
noted. Nicotine yield values come from the Federal Trade Commission’s Tar, Nicotine
and Carbon Monoxide Report from 1999-2005. Nicotine metabolite ratio was logtransformed prior to statistical comparison.
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Figure Legends
Figure 1. Mean ± SEM for smoking topography parameters for pregnant and nonpregnant smokers as measured by the CReSS Desktop Smoking Topography device.
There were no significant differences between groups on any parameter.
Figure 2. Mean ± SD CO boost at 15, 30, 45 and 60 minutes after pregnant and nonpregnant smokers smoked one usual brand cigarette. There were significant effects of
group and time (ps < .05), but no interaction.
Figure 3. Mean ± SEM Modified Cigarette Evaluation Questionnaire subscale scores
immediately after smoking usual brand cigarettes in pregnant and non-pregnant smokers.
An asterisk (*) indicates a significant effect of group (p < .001).
Figure 4. Mean ± SEM scores for the Minnesota Nicotine Withdrawal Scale (MNWS)
total score (top left panel), MNWS item ‘desire or craving to smoke’ (top right panel),
and Questionnaire of Smoking Urges (QSU) Factor 1 and QSU Factor 2 (bottom left and
right panels, respectively) before and 15, 30, 45 and 60 minutes after pregnant and nonpregnant smokers smoked one usual brand cigarette. There was a significant effect of
time on all measures. There was also a significant effect of group for QSU Factors 1 and
2 (ps < .01), but not on MNWS measures, nor were there any interactions.
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Appendix A
Fagerstrӧm Test for Nicotine Dependence
Description: A 6-item measure of intensity of nicotine dependence. Yes/no items are scored 0 or
1 and multiple choice items are scored from 0 to 3. Total scores are calculated by summing the
score of all items and can range from 0-10. Higher scores indicate greater nicotine dependence.

1. How soon after you wake up do you smoke your first
cigarette?

2. Do you find it difficult to refrain from smoking in
places where it is forbidden (such as in church, at the
library, theater or doctor’s office)?

3. Which cigarette would you hate most to give up?

0-5 minutes
6-30 minutes
31-60 minutes
More than 60 minutes
Yes
No

The first one in the
morning
Any other

4. How many cigarettes a day do you smoke?

10 or less
11-20
21-30
31 or more

5. Do you smoke more frequently during the first hours
after waking than during the rest of the day?

Yes

6. Do you smoke when you are so ill that you are in
bed most of the day?

Yes
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No

No

Appendix B
CReSS Desktop Smoking Topography Device
Description: The CReSS device is an 8” X 6” X 5” console with two tubes connected to the front
(Panel A). The tubes extend about three feet and connect to a mouthpiece which holds a cigarette
(Panel B). Individuals smoke the cigarette through the mouthpiece. The device measures and
records a number of smoking topography parameters, namely: (1) number of puffs per cigarette,
(2) puff duration, (3) inter-puff interval, (4) puff volume, and (5) maximum puff velocity. All
data are transferred from the console to a desktop PC via a USB cord.
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Appendix C
Smoking Topography Parameters
Description: A representation of two puffs and corresponding puff topography parameters as
measured by the CReSS Desktop Smoking Topography Device.
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Appendix D
Modified Cigarette Evaluation Questionnaire (mCEQ)
Description: A 12-item questionnaire assessing how smoking a cigarette made the participant
feel. Participants answer each question with a Likert scale ranging from one to seven. An answer
of zero indicates “not at all”, and seven indicates “extremely”. Certain items are averaged to
create subscale scores. The mCEQ is made up of five subscales (i.e., Satisfaction, Psychological
Reward, Aversion, Enjoyment of Respiratory Tract Sensations, and Craving).

Not at all

Subscale

Extremely

Question

Satisfaction

Was smoking satisfying?

1

2

3

4

5

6

7

Satisfaction

Did the cigarette taste
good?
Did you enjoy the
sensations in your throat
and chest?

1

2

3

4

5

6

7

1

2

3

4

5

6

7

Did smoking calm you
down?
Did smoking make you
feel more awake?

1

2

3

4

5

6

7

1

2

3

4

5

6

7

Psychological
Reward

Did smoking make you
feel less irritable?

1

2

3

4

5

6

7

Psychological
Reward

Did smoking help you
concentrate?

1

2

3

4

5

6

7

Psychological
Reward

Did smoking reduce
your hunger for food?

1

2

3

4

5

6

7

Aversion

Did smoking make you
dizzy?
Did smoking make you
nauseous?
Did smoking
immediately reduce your
craving for cigarettes?
Did you enjoy smoking?

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

Enjoyment of
Respiratory
Tract
Sensations
Psychological
Reward
Psychological
Reward

Aversion
Craving
Reduction
Satisfaction
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Appendix E
Minnesota Nicotine Withdrawal Scale (MNWS)
Description: The MNWS measures nicotine withdrawal symptoms. Participants reported on the
presence of a given symptom with an answer of ‘None’, ‘Slight’, ‘Mild’, ‘Moderate’, and
‘Severe’. Responses were then assigned a score of 0 to 4, with 0 representing None and 4
reflecting Severe. Mean withdrawal is derived as the average of seven of the eight symptoms
(range, 0-4), with the item “Desire or Craving to Smoke” analyzed separately (Hughes &
Hatsukami, 1998). Higher scores indicate greater withdrawal or craving.

None
0

1) Angry, irritable, frustrated
2) Anxious, nervous
3) Depressed mood, sad
4) Desire or craving to smoke
5) Difficulty concentrating
6) Increased appetite, hungry, weight
gain
7) Insomnia, sleep problems, awakening
at night
8) Restless
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Slight
1

Mild
2

Moderate
3

Severe
4

Appendix F
Questionnaire of Smoking Urges (QSU)
Description: The QSU is comprised of 10 statements regarding current cravings to smoke.
Participants assigned each statement a number from one to seven. An answer of zero indicates
“strongly disagree”, and seven indicates “strongly agree”. The QSU is scored such that two
factors are derived, with Factor 1 often described as a measure of positive reinforcing effects of
smoking and Factor 2 a measure of the negative reinforcing effects of smoking.. Factor scores
are calculated by averaging scores from the individual item scores that make up each factor
(Factor 1 = six items, Factor 2 = four items). Factor scores range from 1 to 7. Higher scores
indicate greater craving/urges to smoke.

Factor

Question

1

I have a desire for a
cigarette right now

1

Nothing would be better
than smoking a cigarette
right now.
If it were possible, I
probably would smoke
right now.
I could control things
better right now if I
could smoke.

1

2

Strongly
DISAGREE

Strongly
AGREE

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

2

All I want right now is a
cigarette.

1

2

3

4

5

6

7

1

I have an urge for a
cigarette.

1

2

3

4

5

6

7

1

A cigarette would taste
good right now

1

2

3

4

5

6

7

2

I would do almost
anything for a cigarette
right now.

1

2

3

4

5

6

7

2

Smoking would make
me less depressed.

1

2

3

4

5

6

7

1

I am going to smoke as
soon as possible.

1

2

3

4

5

6

7
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